Effect of the BET Protein Inhibitor, RVX-208, on Progression of Coronary Atherosclerosis: Results of the Phase 2b, Randomized, Double-Blind, Multicenter, ASSURE Trial
- 18 September 2015
- journal article
- research article
- Published by Springer Science and Business Media LLC in American Journal of Cardiovascular Drugs
- Vol. 16 (1), 55-65
- https://doi.org/10.1007/s40256-015-0146-z
Abstract
Background Bromodomain and extra-terminal (BET) proteins regulate transcription of lipoprotein and inflammatory factors implicated in atherosclerosis. The impact of BET inhibition on atherosclerosis progression is unknown. Methods ASSURE was a double-blind, randomized, multicenter trial in which 323 patients with angiographic coronary disease and low high-density lipoprotein cholesterol (HDL-C) levels were randomized in a 3:1 fashion to treatment with the BET protein inhibitor RVX-208 200 mg or placebo for 26 weeks. Plaque progression was measured with serial intravascular ultrasound imaging. Lipid levels, safety, and tolerability were also assessed. Results During treatment, apolipoprotein (apo)A-I increased by 10.6 % with placebo (P < 0.001 compared with baseline) and 12.8 % with RVX-208 (P < 0.001 compared with baseline), between groups P = 0.18. HDL-C increased by 9.1 % with placebo (P < 0.001 compared with baseline) and 11.1 % with RVX-208 (P < 0.001 compared with baseline), between groups P = 0.24. Low-density lipoprotein cholesterol (LDL-C) decreased by 17.9 % with placebo (P < 0.001 compared with baseline) and 15.8 % with RVX-208 (P < 0.001 compared with baseline), between groups P = 0.55. The primary endpoint, the change in percent atheroma volume, decreased 0.30 % in placebo-treated patients (P = 0.23 compared with baseline) and 0.40 % in the RVX-208 group (P = 0.08 compared with baseline), between groups P = 0.81. Total atheroma volume decreased 3.8 mm3 in the placebo group (P = 0.01 compared with baseline) and 4.2 mm3 in the RVX-208 group (P < 0.001 compared with baseline), P = 0.86 between groups. A greater incidence of elevated liver enzymes was observed in RVX-208-treated patients (7.1 vs. 0 %, P = 0.009). Conclusion Administration of the BET protein inhibitor RVX-208 showed no greater increase in apoA-I or HDL-C or incremental regression of atherosclerosis than administration of placebo. Trial Registration ClinicalTrials.gov identifier—NCT01067820.Keywords
Funding Information
- Resverlogix Corporation
This publication has 27 references indexed in Scilit:
- Effects of Dalcetrapib in Patients with a Recent Acute Coronary SyndromeThe New England Journal of Medicine, 2012
- Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin TherapyThe New England Journal of Medicine, 2011
- Efficacy and Safety of a Novel Oral Inducer of Apolipoprotein A-I Synthesis in Statin-Treated Patients With Stable Coronary Artery Disease: A Randomized Controlled TrialJournal of the American College of Cardiology, 2011
- A First-in-Man, Randomized, Placebo-Controlled Study to Evaluate the Safety and Feasibility of Autologous Delipidated High-Density Lipoprotein Plasma Infusions in Patients With Acute Coronary SyndromeJournal of the American College of Cardiology, 2010
- RVX-208: A Small Molecule That Increases Apolipoprotein A-I and High-Density Lipoprotein Cholesterol In Vitro and In VivoJournal of the American College of Cardiology, 2010
- Effects of Reconstituted High-Density Lipoprotein Infusions on Coronary AtherosclerosisA Randomized Controlled TrialJAMA, 2007
- Effect of Very High-Intensity Statin Therapy on Regression of Coronary AtherosclerosisJama-Journal Of The American Medical Association, 2006
- Effect of Intensive Compared With Moderate Lipid-Lowering Therapy on Progression of Coronary AtherosclerosisJAMA, 2004
- Effect of Recombinant ApoA-I Milano on Coronary Atherosclerosis in Patients With Acute Coronary SyndromesJAMA, 2003
- High density lipoprotein as a protective factor against coronary heart diseaseAmerican Journal Of Medicine, 1977